This suggests either that PRC2 function at the SOX2 loci is already fully inhibited in translocation positive synovial sarcoma cells, and thus SOX2 expression cannot be upregulated any further, or that other mechanisms are regulating SOX2 expression. The gene discussed is SOX2; the disease is synovial sarcoma.